Advancing Cancer Care for Dogs
We are transforming canine cancer care through ongoing scientific research and innovation in therapeutic treatments.
Peer Reviewed by Nature™: Remarkable Survival Gains for Canine Cancer Patients. See how we work with:
New approaches to the development of cancer therapeutics are urgently needed to improve the current 89% failure rate of novel drugs in clinical trials, and to improve patient outcomes. Spontaneous cancer in companion animals represents a unique opportunity for investigation of novel therapeutics for human and veterinary use
Despite a growing number of targeted cancer treatments in development each year, few are able to reach cancer patients due to the rate at which evidence is generated from human clinical trials
Dog cancer research advances pursuit of drugs for humans and canines
Published June 19, 2023 | Compelling genetic data, increased funding and growing collaborations in the past decade are pushing forward development of cancer drugs for both canines and humans
Could Fido lead us to better cancer drugs?
Despite a growing number of targeted cancer treatments in development each year, few are able to reach cancer patients due to the rate at which evidence is generated from human clinical trials
World’s largest genomic study of canine cancer reveals potential for novel human cancer treatments
Researchers from Stanford AI Health and One Health, the world’s first translational canine cancer care company, published the results from the largest-ever genomic study of canine cancer which revealed a promising path for enhanced human cancer treatments.
There’s no “one-size-fits-all” treatment for cancer. That’s why FidoCure® uses genomic testing to determine the best course of action for your dog’s cancer therapy – beyond standard chemo and radiation.
Precision medicine can offer a hopeful prognosis. FidoCure® was created by dog lovers and scientists on a mission to make effective canine cancer treatment accessible. Our process uses genomic testing in conjunction with tumor type to identify possible cancer-causing mutations. From there, we suggest targeted therapy to precisely attack the cancer cells.
Forrest was diagnosed with splenic cancer and given one month to live.
Through the targeted therapy suggested by FidoCure®, he lived happily for nearly 4 years past his diagnosis.
Forrest, Golden Retriever
Hemophagocytic Histiocytic Sarcoma
Trusted by the Leading Veterinary Oncologists
Thousands of dogs have benefitted from FidoCure® when other options were limited.
Toulouse
“Since starting treatment, Toulouse’s tumors have regressed. FidoCure® brought us hope for Toulouse when we thought we didn’t have any options left.” — Daniel, FL
Lizzie
“Thanks to FidoCure®, Lizzie is 100% active again, eating well, and in remission for 5 months.” — Kimberley and Francois, CT
Gracie
“[Our vet] told us about the One Health Company’s precision medicine solution, FidoCure®… Now, exactly two months later, Gracie’s cancer is in remission.” — The Gonzalez Family, FL
Resources & Education
-
Romulus’ Story: A Guardian Dog’s Cancer Tale
by FidoCure
At FidoCure, we believe every dog deserves a chance to live their best life, even when faced with challenging diagnoses. The story of […]
-
Franklin’s Story: A Rescue Dog Thrives Thanks to Breakthrough Cancer Treatments
by FidoCure
For over nine years, Franklin has been a beloved member of the Noll-Mcclintock family—a funny, smart, and playful 8-year-old rescue dog. […]
-
Dexter’s Story: A Pet Parent's Perspective
by FidoCure
Meet Dexter, a lovable mixed-breed pup who’s been on a journey of resilience and love since his cancer diagnosis five years ago. His […]
-
Data-First Pet Healthcare: How FidoCure is Leveraging Big Data to Improve Canine Cancer Outcomes
by FidoCure
In the fight against canine cancer, one of the most powerful tools at medicine’s disposal is data. Data can help describe genomes, […]
-
The Future of Pet Oncology: How AI-Driven Targeted Therapies are Revolutionizing Cancer Treatment for Dogs
by FidoCure
The global veterinary oncology market has been experiencing remarkable growth, reaching a valuation of $259.4B in 2023. This surge reflects […]
-
Global Impact from the U.S. to Korea at FAVA 2024
by Christina K. Lopes in Vet
We are excited to share that Dr. Lucas Rodrigues, FidoCure's Head of Veterinary Research, will be presenting twice at the 23rd Federation […]